Answers are grounded in this paper and cite their sources.
Agents which prime the neutrophil NADPH oxidase develop during routine storage of whole blood and packed red blood cells. This plasma priming activity can be inhibited by bepafant (WEB 2170), a specific platelet activating factor (PAF) receptor antagonist. Quantitation of the priming agent(s), by a commercially available radioimmunoassay for PAF, reproducibly demonstrated high levels of PAF activity. However, analysis of these plasma samples from stored blood components by gas chromatography/mass spectroscopy did not reveal any 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine. We conclude that the polyclonal antibody to PAF used in these studies may have recognized different epitopes of a family of heterogeneous, biologically active lipids that manifest their effects through the PAF receptor.
No takes yet. Share an insight, caveat, or question.
Silliman et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: